These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11338923)

  • 21. Targeting strategies in cancer gene therapy.
    Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr; 35(4):311-6. PubMed ID: 12673383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors.
    Sullenger BA
    Cytokines Mol Ther; 1996 Sep; 2(3):201-5. PubMed ID: 9384705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA-targeting approaches for neuromuscular diseases.
    Le Roy F; Charton K; Lorson CL; Richard I
    Trends Mol Med; 2009 Dec; 15(12):580-91. PubMed ID: 19906562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribozymes and siRNA for the treatment of diseases of the nervous system.
    Wood MJ; Trülzsch B; Abdelgany A; Beeson D
    Curr Opin Mol Ther; 2003 Aug; 5(4):383-8. PubMed ID: 14513681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoration of protein synthesis in pancreatic cancer cells by trans-splicing ribozymes.
    Kastanos E; Hjiantoniou E; Phylactou LA
    Biochem Biophys Res Commun; 2004 Sep; 322(3):930-4. PubMed ID: 15336553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage.
    Yen L; Svendsen J; Lee JS; Gray JT; Magnier M; Baba T; D'Amato RJ; Mulligan RC
    Nature; 2004 Sep; 431(7007):471-6. PubMed ID: 15386015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNAzymes and their therapeutic possibilities.
    Chan CW; Khachigian LM
    Intern Med J; 2009 Apr; 39(4):249-51. PubMed ID: 19402864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic applications of ribozymes and riboswitches.
    Mulhbacher J; St-Pierre P; Lafontaine DA
    Curr Opin Pharmacol; 2010 Oct; 10(5):551-6. PubMed ID: 20685165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maxizyme technology.
    Iyo M; Kawasaki H; Taira K
    Methods Mol Biol; 2004; 252():257-65. PubMed ID: 15017055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene delivery for lung cancer using nonviral gene vectors.
    Wang JT; Peng DY; Chen M; Ye JS
    Pharmazie; 2007 Oct; 62(10):723-6. PubMed ID: 18236772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
    Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW
    Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach.
    Malerczyk C; Schulte AM; Czubayko F; Bellon L; Macejak D; Riegel AT; Wellstein A
    Gene Ther; 2005 Feb; 12(4):339-46. PubMed ID: 15496960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding.
    Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F
    J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicase-attached novel hybrid ribozymes.
    Kawasaki H; Warashina M; Kuwabara T; Taira K
    Methods Mol Biol; 2004; 252():237-43. PubMed ID: 15017053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. siRNA-based approaches in cancer therapy.
    Devi GR
    Cancer Gene Ther; 2006 Sep; 13(9):819-29. PubMed ID: 16424918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target.
    Li YL; Torchet C; Vergne J; Maurel MC
    Biochimie; 2007 Oct; 89(10):1257-63. PubMed ID: 17703868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hammerhead ribozymes as therapeutic agents for bladder cancer.
    Irie A; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
    Mol Urol; 2000; 4(2):61-6. PubMed ID: 12006244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled, targeted, intracellular expression of ribozymes: progress and problems.
    Rossi JJ
    Trends Biotechnol; 1995 Aug; 13(8):301-6. PubMed ID: 7544984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.